Itau Unibanco Holding S.A.’s Viking Therapeutics VKTX Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-106	Closed	-$5.62K	–	439
2024 Q2	$5.62K	Buy	+106	New	+$6.95K	﹤0.01%	311
2023 Q4	–	Sell	-286	Closed	-$3.17K	–	531
2023 Q3	$3.17K	Sell	286 -4	-1%	-$57	﹤0.01%	459
2023 Q2	$4.7K	Buy	+290	New	+$6.08K	﹤0.01%	490

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Itau Unibanco Holding S.A.'s VKTX Position: Q3 2024 in Review

Itau Unibanco Holding S.A. sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 106 shares — an estimated $5.62K sold.

Itau Unibanco Holding S.A. first reported a position in VKTX in Q2 2023 and held it in 3 quarters. The position peaked at $5.62K in Q2 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Itau Unibanco Holding S.A. reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 106 Viking Therapeutics shares in Q3 2024, an estimated $5.62K.
Itau Unibanco Holding S.A. first reported a position in Viking Therapeutics in Q2 2023 and held it in 3 quarters.
Itau Unibanco Holding S.A.'s Viking Therapeutics position peaked at $5.62K in Q2 2024.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2024, filed 14 Nov 2024.